MDNA vs. FRX, ITH, CRDL, IPA, APM, GXE, GPH, WMD, EQ, and SGW
Should you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include Fennec Pharmaceuticals (FRX), International Tower Hill Mines (ITH), Cardiol Therapeutics (CRDL), ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Gear Energy (GXE), Graphite One (GPH), WeedMD (WMD), EQ (EQ), and Shoal Games (SGW). These companies are all part of the "pharmaceutical products" industry.
Medicenna Therapeutics vs. Its Competitors
Medicenna Therapeutics (TSE:MDNA) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.
Fennec Pharmaceuticals received 16 more outperform votes than Medicenna Therapeutics when rated by MarketBeat users. Likewise, 69.80% of users gave Fennec Pharmaceuticals an outperform vote while only 68.22% of users gave Medicenna Therapeutics an outperform vote.
Medicenna Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.
Fennec Pharmaceuticals has a net margin of -2.30% compared to Medicenna Therapeutics' net margin of -533,640.00%. Fennec Pharmaceuticals' return on equity of 29.94% beat Medicenna Therapeutics' return on equity.
Fennec Pharmaceuticals has higher revenue and earnings than Medicenna Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.
13.0% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 52.8% of Fennec Pharmaceuticals shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Fennec Pharmaceuticals had 3 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 4 mentions for Fennec Pharmaceuticals and 1 mentions for Medicenna Therapeutics. Medicenna Therapeutics' average media sentiment score of 0.67 beat Fennec Pharmaceuticals' score of 0.34 indicating that Medicenna Therapeutics is being referred to more favorably in the media.
Summary
Fennec Pharmaceuticals beats Medicenna Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Medicenna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medicenna Therapeutics Competitors List
Related Companies and Tools
This page (TSE:MDNA) was last updated on 6/13/2025 by MarketBeat.com Staff
